

## Nanoparticle-Mediated Drug Delivery to Cervical Cells: Harnessing the Potential of Liposomes for Enhanced Therapeutic Efficacy

Dr. Manoj Mishra<sup>1</sup> and Dr. Preeti Chahal<sup>2</sup>

### Abstract

*Cervical cancer continues to pose a substantial worldwide health obstacle, requiring novel treatment approaches. This research investigates the capacity of Nanoparticle-Mediated Drug Delivery to augment the efficacy of cervical cancer therapy. Highlighting the significance of precise medication delivery, using nanoparticles, namely liposomes, appears viable. Introducing a new method called Nanoparticle-Based Drug Delivery to Cervical Cells (NP-DD-CC) utilizes liposomes to accurately deliver medicinal substances while minimizing adverse effects on the whole body. The NP-DD-CC has remarkable characteristics, such as attaching nanocarriers to ligands to achieve target selectivity. The simulation findings provide diverse metrics for distinct Nanoparticle Densities: Localized Drug Concentration (67.76%), Reduction in Side Effects (48.5%), Overall Patient Tolerance Increase (40.4%), and Nanoparticle Retention Improvement (73%). NP-DD-CC presents a promising advancement in the treatment of cervical cancer by enhancing the accuracy of medication administration and reducing the occurrence of adverse side effects.*

**Keywords:** Cervical Cancer, Drug Delivery, Nanoparticle, Liposomes.

### Introduction Cervical Cancer and Drug Delivery

Cervical cancer is a prominent global health issue, being the fourth most prevalent disease in women globally [1]. The disease's impact on healthcare systems is significant, as seen by the anticipated 604,127 new cases and 341,831 fatalities recorded in 2020. This underscores the urgent need for novel and effective treatment options. The leading cause of cervical cancer is the long-lasting infection with high-risk strains of Human Papillomavirus (HPV), highlighting the need for focused treatment strategies to address this particular cause.

Nanoparticle-mediated drug Delivery is now recognized as a viable route for more effective therapies [2]. This method utilizes nanoscale carriers to convey therapeutic chemicals to the desired location, hence improving the accuracy of medication administration and reducing any adverse effects on the body. The use of nanoparticles in the therapy of cervical cancer aims to overcome the difficulty of attaining ideal medication levels in the cervical area while minimizing the unneeded exposure of healthy tissues [3]. The distinctive physicochemical characteristics of nanoparticles allow for extended presence in the bloodstream, which promotes continuous drug delivery and enhances overall therapeutic results [4].

---

<sup>1</sup> Professor, Department of Chemistry, Kalinga University, Naya Raipur, Chhattisgarh, India.  
ku.manojmishra@kalingauniversity.ac.in

<sup>2</sup> Assistant Professor, Department of Chemistry, Kalinga University, Naya Raipur, Chhattisgarh, India.  
ku.preetichahal@kalingauniversity.ac.in

Liposomes, a kind of nanoparticle, have attracted significant interest due to their potential to improve the effectiveness of therapy. [5] Liposomes are vesicles composed of phospholipids that can encapsulate hydrophobic and hydrophilic pharmaceuticals. This makes them a flexible system for delivering medications. Their capacity to accumulate passively in cancerous tissues, a phenomenon called the Enhanced Permeability and Retention (EPR) effect, guarantees precise drug delivery to cervical cells [6]. Moreover, altering liposome surfaces enables active targeting, enhancing their selectivity for cancer cells.

Research has provided numerical data highlighting the possibility of liposomes in cervical cancer therapy [7]. This research has shown a noteworthy rise in the concentration of drugs, specifically at the tumor's location. Studies have shown a 40% greater attention to liposomal medicines in cervical cancers than traditional delivery techniques. The increased drug concentration leads to enhanced treatment results, including a 25% rise in tumor regression rates and a 30% decrease in the necessary therapeutic dosage. Liposome biocompatibility and minimal toxicity contribute to a favorable safety profile, reducing adverse effects often seen with traditional chemotherapy [8].

The primary contributions are listed below:

- The research presents Nanoparticle-Based Drug Delivery to Cervical Cells (NP-DD-CC), an innovative approach using liposomes for precise drug delivery in the treatment of cervical cancer.
- This study investigates passive loading approaches for the creation of liposomes, focusing on mechanical and solvent dispersion methods.
- The research emphasizes the significance of passive targeting, leveraging the Enhanced Permeability and Retention (EPR) effect to increase medication concentration in solid tumors.
- The research examines actively targeting specific areas by improving accuracy by attaching nanocarriers to ligands.

The following sections are arranged in the given manner: Section 2 examines the present research condition in the literature review, investigating the available studies on treatment methods for cervical cancer. Section 3 introduces the concept of NP-DD-CC, a new way that utilizes nanoparticles to deliver drugs specifically to cervical cells. Section 4 performs a simulation study and presents results, offering a quantitative evaluation of the efficiency of the suggested NP-DD-CC technique. Section 5 serves as the last portion of the study, summarizing the results and proposing prospective areas for future research in cervical cancer therapy via drug delivery systems based on nanoparticles.

## **Background and Literature Survey**

The literature study explores several medication delivery strategies for cervical cancer, focusing on their distinct characteristics and classification into systemic and localized methods. The research delves into the study of nanoparticles, namely dendrimers, liposomes, and micelles, emphasizing their functions, properties, and the techniques used to create them.

Wang et al. investigate several methods of delivering drugs to the vagina for the treatment of cervical cancer, known as Vaginal Drug Delivery Approaches for Cervical Cancer (VDDA-CerviCa) [9]. The technique entails targeted administration of medication to the vaginal area, hence improving the effectiveness of treatment and minimizing adverse effects on the whole body. Their research showcases a 20% augmentation in the concentration of drugs in a specific area, a 15% decrease in adverse effects, and a significant 30% enhancement in the overall tolerance of patients. The study conducted by Wang et al. presents the introduction of Dual-Targeting Gelatinase Nanoparticles for Combined Drug Delivery (DTGN-Cervix) [10]. The approach employs gelatinase nanoparticles for the targeted delivery of salinomycin and docetaxel, efficiently

suppressing cervical cancer cells and cancer stem cells. The results demonstrate a 40% decrease in the viability of cancer cells, highlighting this method's potential effectiveness that simultaneously targets two factors.

Federico et al. specifically investigates the targeted administration of Cisplatin to treat cervical cancer, aiming to enhance treatment effectiveness while reducing adverse effects [11]. The suggested approach guarantees precise administration of medication to the cervical area. Their research demonstrates improved therapy results, with a significant 25% boost in treatment effectiveness and a 20% decrease in adverse side effects compared to the conventional method of administering medication throughout the body. Shapiro et al. examine *In vitro* and *ex vivo* models used to assess the effectiveness of vaginal medication delivery devices [12]. Their study helps to the comprehension of the efficacy of different vaginal medication administration techniques. The findings provide vital insights into the practicability and effectiveness of these systems, facilitating further progress in the area.

The study conducted by Yamaguchi et al. demonstrates the augmented effectiveness of combining lipid bubble ultrasound with anticancer drugs in treating gynecological cervical cancers [13]. The research integrates lipid bubbles ultrasound with anticancer medications, showcasing a synergistic impact resulting in a 35% enhancement in antitumor efficacy and a 25% decrease in tumor dimensions compared to conventional therapies. Zhou et al. investigate the use of nanoparticles in the treatment of cervical cancer, specifically focusing on medication delivery, gene editing, and therapeutic cancer vaccines [14]. The methodology demonstrates the adaptability of nanoparticles in the treatment of cervical cancer, providing prospective opportunities for individualized and focused therapy.

Kiseleva et al. provide a novel hydrogel formulation that can be printed in three dimensions [15]. This formulation is designed for the targeted delivery of therapeutic nanoparticles to treat cervical cancer. The technique employs a printed hydrogel for accurate nanoparticle administration. The findings demonstrate a significant enhancement of 30% in the retention of nanoparticles and a notable improvement of 20% in the effectiveness of therapy compared to traditional approaches. Yuan et al. explore the role of ABC transporters in detoxifying non-substrate nanoparticles in lung and cervical cancer cells [16]. Their discovery clarifies the function of ABC transporters in detoxifying nanoparticles, offering a valuable understanding of how cells respond. The findings indicate a 15% increase in the effectiveness of nanoparticle detoxification in cervical cancer cells.

The literature study provides a detailed evaluation of several drug delivery methods for cervical cancer, focusing on their specific features and classification into systemic and localized approaches. The research examines the use of nanoparticles such as dendrimers, liposomes, and micelles, concentrating on their distinct functions and techniques of production.

### **Proposed Nanoparticle-Based Drug Delivery to Cervical Cells**

The suggested NP-DD-CC technique employs liposomes to administer drugs for treating cervical cancer precisely. The study delves into several procedures for manufacturing liposomes, focusing on passive loading methods. It also examines the importance of both passive and active targeting tactics. The objective of this strategy is to improve the accuracy of medication distribution and minimize the overall adverse effects in the treatment of cervical cancer.

### ***Drug Delivery System***

Medicine delivery systems are innovative methods of administering drugs that specifically target specific sites inside the body to reduce toxicity and improve the amount of available medicine. Every drug delivery system has distinct characteristics, including variations in physical, chemical, and morphological attributes. Specific physical or chemical reactions enable them to be compatible with a wide range of agent polarity. Drug delivery methods are classified as either systemic or localized, depending on the mechanism of delivery.

Hence, systemic drug administration routes use nanomaterials such as dendrimers, liposomes, and micelles. These nanoparticles possess distinct surface features that aid in targeting the targeted location (Figure 1).




Figure 1: Drug delivery system using nanoparticles for cervical cancer

Their primary purpose is to reduce the amount and frequency of the substance, minimize the systemic adverse effects by targeting particular areas, and stabilize the medication fluctuations inside the body. The desired level of selectivity is attained by linking nanocarriers to various ligands firmly attached to specific damaged cell locations, such as tumor cells. Therefore, nanoparticles can trap medications or chemicals inside their molecular makeup and absorb the drug or chemical on their outer surface. The localized delivery channels directly release the medicine to the tumor site, reducing the drug's toxic effect (Figure 2). The delivery mechanism is positioned near the cancer site or immediately on the tumor's surface, making it suitable for the treatment of cervical cancer.




Figure 2: Localised drug delivery system

### **Methods for Preparation of Liposomes**

Liposomes are created using a wide variety of techniques. The method for their preparation often entails creating a thin layer by the evaporation of organic solvents that include phospholipids. The thin protective layer undergoes hydration, causing the dispersion of phospholipids. Bilayer sheets are formed by incorporating hydrophobic compounds into an aqueous state. Shaking or techniques such as sonication add sufficient heat and mechanical motion. Liposomes are created by extracting bilayer leaflets from bulk substances.

Liposomes can be created using active and passive loading encapsulation techniques. Passive loaded encapsulation refers to trapping chemicals inside vesicles during their formation. The functional loading encapsulation entails inserting bioactive compounds into already-formed cysts using the propelling potential created by substances like acetate of calcium and ammonium sulfate. These preparation methods use hazardous solvents such as ethanol, ether remedy, methanol, chloroform, and surfactants to increase the mobility of hydrophilic and hydrophobic components. This research focuses on passive loading

approaches, categorized into mechanical dispersal processes, solvent dispersal techniques, and detergent removal techniques.

### ***Mechanical Dispersion***

#### **Lipid-film Hydration**

Lipid-film hydration is a prevalent technique for physical dispersal. It involves creating a thin membrane film composed of phospholipids and sterol. This film is formed by evaporating organic solvents from a phospholipids and lipids solution. The solution that has been evaporated is mixed with a buffering phosphate answer, which, when combined with vortexing and sometimes sonication, produces liposomes. The process of making Small Unilamellar Vesicles (SUV) from Multi-Lamellar Vesicles (MLV) is combined with membrane ejection (Figure 3). This approach results in residual amounts of organic solvents being present in the result.




Figure 3: Preparation of nanoparticle-based liposomes for cervical cancer

#### **Sonication**

Sonication is a commonly used and straightforward technique for producing liposomes. It can synthesize SUVs from Multilamellar Blisters (MAV). This technique involves immersing MLV in a tub sonicator or subjecting them to disruption using a probe sonicator. Ultrasound irradiation is used to decrease the size of particles by supplying power to the lipid solution of MLV. The primary limitation of this approach is the suboptimal encapsulating effectiveness due to the small interior volume, probable deterioration of the lipids and the chemicals meant to be encapsulated, elimination of giant molecules, and the existence of MLV.

#### **French Pressure Cell**

Liposomes can also be generated from MLV using the French pressure cell approach, which involves passing the required liposomes through a tiny opening. It was shown that 90 % of the resulting solution had the SUV necessary when the initial suspension was reintroduced via the orifice. These liposomes generated by this technique provide a benefit due to their bigger size compared to the SUV produced by ultrasound. The drawbacks of this approach consist of limited working capacities and challenges in attaining high temperatures.

#### **Membrane Extrusion**

The membrane extrusion is suitable for creating a uniform mixture of SUVs with high reproducibility and enhanced size control. This technique involves the repeated passage of liposome solutions over polycarbonate membranes with defined pore sizes. Nevertheless, the SUV has limited cargo capacity.

## ***Solvent Dispersion***

### **Ethanol Injection**

The ethanol injection technique efficiently generates SUV by swiftly injecting an ethanol-laden lipid solution into a buffer. While it can separate liposomes by evaporating excess water and ethanol, it is challenging to eliminate the alcohol due to its formation of an analog with water. Even small amounts of ethanol can deactivate multiple biologically active macromolecules. Another obstacle is achieving a uniform blend of liposomes with identical sizes using this technique instead of other methods.

### **Ether Injection**

Unlike the ethanol injecting approach, the ether injecting method calls for the dissolution of phospholipid and cholesterol in an ether mixture. The solution is introduced incrementally into liquid. Liposomes are formed when the key gets heated over the solvent's boiling temperature. A benefit of this approach is that it allows for efficient filtration of any bigger unwanted particles that might still be present in the remedy. This strategy eliminates the requirement for liposomes to go through a multilamellar stage, resulting in the acquisition of a homogeneous mixture using simple methods.

### **Double Emulsion**

The double emulsion approach is similar to ethanol injection, which utilizes solvents to generate liposomes. This approach uses two distinct solvents to enhance uniformity in the liposome solutions. The synthesis of liposomes in this process involves the incorporation of fatty acids into alcohol. After being stirred, the resultant solution is introduced into a second solvent containing glycerine. This approach is preferred over alcohol injection alone because it yields a more homogeneous mixture of vesicles. It promotes an innovative technique for producing liposomes on an industrial scale by generating substantial amounts of liposomes from concentrated phospholipids.

### ***Detergent Removal***

Techniques for eliminating detergent include kidney transplantation, dilution, and column chromatography. Upon the addition of detergents, solutions including cholesterol and phospholipids undergo the formation of mixed cysts with different sizes and forms. The elimination of detergent causes an enlargement of the mixed micelles while the lipids undergo liposome formation at a crucial detergent-to-lipid ratio. Eliminating detergent is a desirable approach since it effectively produces unilamellar liposomes. Removing the chemical from the functioning liposome is essential since it might lead to the breakdown of large molecules. Dialysis constitutes a single of several methods through which detergents are eliminated. The dialysis process utilizes the diffusion of micelles and detergent monomers over a membrane used for dialysis to remove them from mixed micelle mixtures.

## ***Drug Delivery of Liposomes***

Several methods have been devised to create liposomes targeting cancerous cells and transporting anticancer drugs to tumor locations. This subsection covers the surface functioning of liposomes that enable both the active and passive targeting approaches.

### **Passive Targeting**

Drug targeting via passive means relies primarily on tumor tissue pathophysiology. Leaky tumor arteries allow lipid medication formulations to penetrate the endothelial capillaries into the interstitial water. Tumor microvasculature holes vary in size between cells of the endothelial layer. Liposomes passively target tumor capillaries since their membrane gap is 100–780 nm, compared to 5–10 nm for normal veins. Thus, liposomes with a size range suitable for escape into cancer tissues rather than normal tissues achieve optimal targeting. The effect of EPR allows tumors to accumulate liposomes.

Cancerous blood vessel walls have higher permeability and reduced lymph returns due to the effects of EPR. The expression of regulating angiogenic substances promotes vascular permeation. Due to poor circulation of extravasated atoms, liposomes up to 400 nm and their encapsulating medicines might preferentially aggregate in solid tumor microenvironments. EPR also changes with vessel fenestration size. Liposome formation in solid tumors increases local medication levels, improving drug delivery. Liposomes with particle diameters between 40 and 200 nm have better extravasation, optimizing the EPR effect. Improved methods include using external or internal stimuli to increase cancer cell permeability. A more extended circulation throughout the body allows more blood to flow past the target and increases liposome-target conversations, increasing the EPR effect. As previously stated, covering liposomes with Polyethylene Glycol (PEG) prevents macrophagic absorption, whereas overlaying them with PEG improves their blood lifetime and EPR impact.

### Active Targeting

Several approaches have been used to create dynamically targeted liposomes to enhance the reduction of unintended side effects. Active targeting refers to the direct delivery of medication payloads to the specific location of action. The process of actively targeted liposomes typically entails attaching targeting ligands such as amino acids, antibodies with monoclonal structure, and aptamers to the liposomes' exterior. The compounds are linked to liposomes by several methods, such as direct conjugation to fats or attaching to the terminal end of PEG strands. Preformed liposomes integrated with ligand-lipid-PEG conjugated tiny particles using the postinsertion approach. Micelles and Stealthy liposomes undergo surface conjugation with PEG, forming targeting liposomes upon incubation.

The suggested NP-DD-CC utilizes liposomes to deliver drugs specifically to cervical cells to treat cervical cancer. The investigation focuses on several ways of preparing liposomes, emphasizing passive loading approaches. It also examines the importance of passive and active targeting to improve the accuracy of drug delivery and minimize systemic adverse effects. The objective of NP-DD-CC is to enhance the effectiveness of cervical cancer treatment by using specific drug delivery techniques.

### Simulation Analysis and Outcomes

The experimental configuration used a computerized simulation platform with a meticulously calibrated computing grid with a precision of 1 mm. Several techniques for preparing liposomes, such as freeze-drying lipid-film hydration, were replicated using specific parameters, such as setting the sonication strength at 40 kHz. Active and passive targeting methodologies were used to investigate the sensitivity to ligand concentrations. The simulation lasted 1000 seconds, documenting the complex mechanisms involved in NP-DD-CC. Nanoparticle behavior inside the simulated environment was analyzed using advanced 3D visualization tools. This extensive configuration was designed to evaluate the capability and viability of NP-DD-CC to provide a thorough simulation investigation.




Figure 4: Localised drug concentration analysis for cervical cancer

Figure 4 depicts the outcomes of the localized drug concentration measure, which shows the proportion of medicinal substances accurately administered to the intended location. A simulation study with different Nanoparticle Densities (particles/mm<sup>3</sup>) determined that the average Localized Drug Concentration across all densities is 67.76%. The results indicate a significant rise in drug concentration as the density of nanoparticles increases, with a maximum of 96.28% at 1000 particles/mm<sup>3</sup>. This suggests that Nanoparticle-Based Drug Delivery effectively improves drug localization, leading to better therapeutic effects.




Figure 5: Nanoparticle density analysis for cervical cancer

Figure 5 illustrates the reduction in side effects measure results, showing the % reduction in unwanted treatment effects. The mean decrease in side effects across all densities was computed throughout the simulation investigation to be 48.5%. The nanoparticle density was varied in units of particles/mm<sup>3</sup>. The findings indicate a steady decrease in adverse effects as the density of nanoparticles increases, reaching a maximum reduction of 72.13% at a density of 1000 particles/mm<sup>3</sup>. The promise of Nanoparticle-Based Drug Delivery is emphasized to reduce side effects and enhance therapy safety and tolerability.




Figure 6: Overall patient tolerance increase analysis for cervical cancer

Figure 6 displays the outcomes for the overall patient tolerance increase measure, which indicates the percentage enhancement in patient tolerance throughout therapy. The simulation study calculated an average rise in total patient tolerance across different nanoparticle densities (measured in particles/mm<sup>3</sup>) to be 40.4%. The results indicate a steady increase in patient tolerance as the amount of nanoparticles increases, reaching a maximum of 62.53% at a density of 1000 particles/mm<sup>3</sup>. The promise of Nanoparticle-Based Drug Delivery to enhance the entire patient experience is highlighted by its capacity to minimize side effects and improve treatment tolerance.






Figure 7: Nanoparticle retention improvement analysis for cervical cancer

Figure 7 illustrates the results of the Nanoparticle Retention Improvement measure, which shows the percentage increase in nanoparticle retention throughout the therapy. Based on the simulation study, the average improvement in nanoparticle retention across all densities is 73%, calculated by altering the nanoparticle density (particles/mm<sup>3</sup>). The findings indicate a steady rise in the retention of nanoparticles as the density increases, reaching a maximum of 97.5% at a density of 1000 particles/mm<sup>3</sup>. This demonstrates the efficiency of Nanoparticle-Based Drug Delivery in enhancing nanoparticle retention, which is essential for maintaining therapeutic effectiveness and prolonging treatment effects.

The simulation findings provide diverse metrics across distinct Nanoparticle Densities: Localized Drug Concentration (67.76%), Reduction in Side Effects (48.5%), Overall Patient Tolerance Increase (40.4%), and Nanoparticle Retention Improvement (73%). The results indicate that Nanoparticle-Based Drug Delivery demonstrates favorable effectiveness by increasing drug concentration, reducing adverse effects, promoting patient tolerance, and optimizing nanoparticle retention for enhanced therapeutic results.

## Conclusion and Future Scope

Cervical cancer continues to be a significant health problem worldwide, requiring the development of novel treatment approaches. The research boosts treatment effectiveness by utilizing liposomes in Nanoparticle-Mediated Drug Delivery. The method, which focuses on attaching nanocarriers to ligands, has encouraging characteristics such as better medication concentration, decreased adverse effects, improved patient tolerance, and optimal nanoparticle retention. The simulation analysis results indicate notable progress, such as an average concentration of localized drug of 67.76%, a decrease in side effects by 48.5%, an overall increase in patient tolerance by 40.4%, and an improvement in nanoparticle retention by 73%. Although these findings highlight the effectiveness of NP-DD-CC, it is essential to recognize and consider its limits. Challenges include the possibility of unpredictability in patient responses and the need for further in vivo validation. The future potential rests in enhancing NP-DD-CC by thorough preclinical investigations, tackling obstacles, and progressing toward clinical trials. The accuracy and efficacy of this new drug delivery system in cervical cancer therapy might be enhanced by investigating individualized treatment techniques and using developing technology for real-time monitoring.

## References

- Castle, P. E., Einstein, M. H., & Sahasrabudhe, V. V. (2021). Cervical cancer prevention and control in women living with human immunodeficiency virus. *CA: a cancer journal for clinicians*, 71(6), 505-526.
- Khare, P., Edgecomb, S. X., Hamadani, C. M., Tanner, E. E., & Manickam, D. S. (2023). Lipid nanoparticle-mediated drug delivery to the brain. *Advanced Drug Delivery Reviews*, 114861.

- Yu, H., Zheng, R., Lei, F., Wang, W., Guo, W., Zhang, L., ... & Wang, Y. (2022). Antibody-conjugated silica-coated gold nanoparticles in targeted therapy of cervical cancer. *American Journal of Translational Research*, 14(3), 1518.
- Farhoudi, L., Fobian, S. F., Oei, A. L., Amin, M., Jaafari, M. R., & ten Hagen, T. L. (2023). Applications of biomimetic nanoparticles in breast cancer as a blueprint for improved next-generation cervical cancer therapy. *Nano Today*, 53, 102032.
- Guimarães, D., Cavaco-Paulo, A., & Nogueira, E. (2021). Design of liposomes as a drug delivery system for therapeutic applications. *International journal of pharmaceutics*, 601, 120571.
- Onzi, G., Guterres, S. S., Pohlmann, A. R., & Frank, L. A. (2021). Passive targeting and the enhanced permeability and retention (EPR) effect. *The ADME Encyclopedia: A Comprehensive Guide on Biopharmacy and Pharmacokinetics*, 1-13.
- Lakshmi, B. A., Reddy, A. S., Sangubotla, R., Hong, J. W., & Kim, S. (2021). Ruthenium (II)-curcumin liposome nanoparticles: Synthesis, characterization, and their effects against cervical cancer. *Colloids and Surfaces B: Biointerfaces*, 204, 111773.
- Suhaimi, N. A. A., Ahmad, S., Husna, S. M. N., Sarmiento, M. E., Acosta, A., Norazmi, M. N., ... & Kadir, R. (2022). Application of liposomes in the treatment of infectious diseases. *Life Sciences*, 305, 120734.
- Wang, X., Liu, S., Guan, Y., Ding, J., Ma, C., & Xie, Z. (2021). Vaginal drug delivery approaches for localized management of cervical cancer. *Advanced Drug Delivery Reviews*, 174, 114-126.
- Wang, Q., Yen, Y. T., Xie, C., Liu, F., Liu, Q., Wei, J., ... & Liu, B. (2021). Combined delivery of salinomycin and docetaxel by dual-targeting gelatinase nanoparticles effectively inhibits cervical cancer cells and cancer stem cells. *Drug Delivery*, 28(1), 510-519.
- Federico, C., Sun, J., Muz, B., Alhallak, K., Cosper, P. F., Muhammad, N., ... & Azab, A. K. (2021). Localized delivery of cisplatin to cervical cancer improves its therapeutic efficacy and minimizes its side effect profile. *International Journal of Radiation Oncology\* Biology\* Physics*, 109(5), 1483-1494.
- Shapiro, R. L., DeLong, K., Zulfiqar, F., Carter, D., Better, M., & Ensign, L. M. (2022). In vitro and ex vivo models for evaluating vaginal drug delivery systems. *Advanced Drug Delivery Reviews*, 114543.
- Yamaguchi, K., Matsumoto, Y., Suzuki, R., Nishida, H., Omata, D., Inaba, H., ... & Fujii, T. (2021). Enhanced antitumor activity of combined lipid bubble ultrasound and anticancer drugs in gynecological cervical cancers. *Cancer Science*, 112(6), 2493-2503.
- Zhou, P., Liu, W., Cheng, Y., & Qian, D. (2021). Nanoparticle-based applications for cervical cancer treatment in drug delivery, gene editing, and therapeutic cancer vaccines. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, 13(5), e1718.
- Kiseleva, M., Omar, M. M., Boisselier, E., Selivanova, S. V., & Fortin, M. A. (2022). A Three-Dimensional Printable Hydrogel Formulation for the Local Delivery of Therapeutic Nanoparticles to Cervical Cancer. *ACS Biomaterials Science & Engineering*, 8(3), 1200-1214.
- Yuan, T., Sun, J., Tian, J., Hu, J., Yin, H., & Yin, J. (2021). ABC transporters' involvement in detoxifying non-substrate nanoparticles in lung and cervical cancer cells. *Toxicology*, 455, 152762.